Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Stock Quote Today & Recent News SANOFI SNY

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

The Power Play by The Market Herald
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (NDAQ:SNY)

Fundamentals Snapshot (NDAQ:SNY)

Current News (NDAQ:SNY)

Dupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Prurigo Nodularis

PR Newswire November 11, 2022

Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old

PR Newswire October 11, 2022

Sanofi US enters into co-promotion agreement with Provention Bio, Inc. to launch teplizumab, an investigational disease-modifying therapy for type 1 diabetes

PR Newswire October 6, 2022

Dupixent® (dupilumab) Approved by FDA as the First and Only Treatment Indicated for Prurigo Nodularis

PR Newswire September 28, 2022

Positive Dupixent® (dupilumab) Phase 3 Data in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Published in The Lancet

PR Newswire September 15, 2022

Dupixent® (dupilumab) Late-breaking Phase 3 Data at the EADV 2022 Congress Showed Significant Improvements in Signs and Symptoms of Prurigo Nodularis

PR Newswire September 8, 2022

Late-Breaking Dupixent® (dupilumab) Data at ERS 2022 Show Consistent Efficacy and Safety Profile for Up to Two Years in Children Aged 6 to 11 Years with Moderate-to-severe Asthma

PR Newswire September 5, 2022

Sanofi higher dose flu vaccines preferentially recommended for adults 65+ in CDC Morbidity and Mortality Weekly Report

PR Newswire August 26, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Sanofi - SNY

Newsfile August 12, 2022

Bullboard Posts (NDAQ:SNY)

Cough Syrup Market Business Challenges and Opportunities

The global cough syrup market size reached US$ 5.4 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 7...
RahulGautam - November 21, 2022

Sanofi and Covid19? WPD Pharma...

Sanofi could easily buy WPD Pharma, who develop a Covid19-drug called WP1122. Did you read this?
Blocky - January 8, 2021

Happy new year Do your Own DD
Rossaporino - January 2, 2021

Bonvoyage12.....Lying Pumper

Ignore this clown as he posts lies trying to mislead investors about the actual state of the company...he also posts this same BS on...
Mil_Man54 - December 26, 2020

Vaccine Stocks - Can the President Overrule the FDA?

An approval cycle that typically takes years is being expedited. In the case of the 2020 pandemic, the FDA  has shortened standard...
schoolofrock - October 7, 2020

Room to run?

Tough market these days but.... Hydroxyquinoline for potential covid co-treatment And now the vaccine deal... Seems promising ...
Gbathat - March 27, 2020